University of California, San Diego, Department of Medicine, Division of Rheumatology, Allergy and Immunology, La Jolla, CA 92093-0732, USA.
Ther Adv Respir Dis. 2011 Jun;5(3):183-94. doi: 10.1177/1753465811400489. Epub 2011 Mar 10.
A number of therapeutic agents are available for the treatment of asthma, including inhaled corticosteroids, long- and short-acting beta-agonists, leukotriene-modifying agents, long- and short-acting anticholinergic agents, chromones, theophylline, allergen immunotherapy, and oral corticosteroid therapy. All available therapies, despite their proven efficacy, are purely symptomatic including the topical steroids. This issue has led to the development of several biologic agents to aid in asthma management and to potentially alter the course of the disease by interfering with specific aspects of inflammation which may modify remodeling in the airways. Monoclonal antibodies have offered a class of therapeutic agents that enhance treatment options for patients with moderate-to-severe persistent asthma. As such, this article provides an overview of present and future monoclonal antibody therapies for the treatment of patients with severe asthma.
有许多治疗药物可用于治疗哮喘，包括吸入性皮质类固醇、长效和短效β-激动剂、白三烯修饰剂、长效和短效抗胆碱能药物、色酮类、茶碱、过敏原免疫疗法和口服皮质类固醇治疗。所有可用的治疗方法，尽管已被证明有效，但都是纯粹的对症治疗，包括局部类固醇。这个问题导致了几种生物制剂的发展，以帮助管理哮喘，并通过干扰炎症的特定方面来潜在地改变疾病的进程，这可能会改变气道的重塑。单克隆抗体提供了一类治疗药物，为中重度持续性哮喘患者的治疗提供了更多选择。因此，本文概述了目前和未来用于治疗严重哮喘患者的单克隆抗体治疗方法。
